Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.992 |
High Similarity |
NPD943 |
Approved |
0.9167 |
High Similarity |
NPD651 |
Clinical (unspecified phase) |
0.8777 |
High Similarity |
NPD1511 |
Approved |
0.8672 |
High Similarity |
NPD9269 |
Phase 2 |
0.8652 |
High Similarity |
NPD1512 |
Approved |
0.8603 |
High Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8378 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8367 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8359 |
Intermediate Similarity |
NPD9268 |
Approved |
0.8333 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8309 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8299 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8248 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.8243 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8195 |
Intermediate Similarity |
NPD1470 |
Approved |
0.8188 |
Intermediate Similarity |
NPD1607 |
Approved |
0.803 |
Intermediate Similarity |
NPD1201 |
Approved |
0.8028 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7984 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7958 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7958 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7898 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7877 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.78 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7794 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7778 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7771 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7712 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7703 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7643 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7639 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7639 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7639 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7639 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7638 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7638 |
Intermediate Similarity |
NPD74 |
Approved |
0.7635 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7625 |
Intermediate Similarity |
NPD7054 |
Approved |
0.761 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7584 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7578 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7559 |
Intermediate Similarity |
NPD9264 |
Approved |
0.7559 |
Intermediate Similarity |
NPD9263 |
Approved |
0.7559 |
Intermediate Similarity |
NPD9267 |
Approved |
0.7559 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7554 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7546 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7531 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7517 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD6190 |
Approved |
0.75 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7485 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7444 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7432 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7432 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7419 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7419 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.741 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7405 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7389 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7376 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7338 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7317 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7308 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7305 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7293 |
Intermediate Similarity |
NPD9281 |
Approved |
0.729 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7267 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7266 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7255 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7244 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD9261 |
Approved |
0.7233 |
Intermediate Similarity |
NPD919 |
Approved |
0.7219 |
Intermediate Similarity |
NPD3300 |
Phase 2 |
0.7206 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7172 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7165 |
Intermediate Similarity |
NPD940 |
Approved |
0.7165 |
Intermediate Similarity |
NPD846 |
Approved |
0.7153 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7153 |
Intermediate Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7133 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7124 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7124 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7124 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7124 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7095 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7095 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7083 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7075 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7071 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7037 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD920 |
Approved |
0.7013 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7012 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD2798 |
Approved |
0.6988 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6964 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6943 |
Remote Similarity |
NPD3226 |
Approved |
0.6933 |
Remote Similarity |
NPD9570 |
Approved |
0.6918 |
Remote Similarity |
NPD411 |
Approved |
0.6917 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6908 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6892 |
Remote Similarity |
NPD1933 |
Approved |
0.6887 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6879 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD257 |
Approved |
0.6875 |
Remote Similarity |
NPD258 |
Approved |
0.6871 |
Remote Similarity |
NPD520 |
Approved |
0.6863 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6863 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6839 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.6828 |
Remote Similarity |
NPD9569 |
Approved |
0.6826 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6821 |
Remote Similarity |
NPD6100 |
Approved |
0.6821 |
Remote Similarity |
NPD6099 |
Approved |
0.6816 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD2654 |
Approved |
0.6794 |
Remote Similarity |
NPD1237 |
Approved |
0.6786 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6782 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6781 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6779 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6776 |
Remote Similarity |
NPD7266 |
Discontinued |
0.6763 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6761 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6755 |
Remote Similarity |
NPD3299 |
Clinical (unspecified phase) |
0.6741 |
Remote Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.6738 |
Remote Similarity |
NPD2932 |
Approved |
0.6738 |
Remote Similarity |
NPD3019 |
Approved |
0.6731 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6714 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6713 |
Remote Similarity |
NPD3972 |
Approved |
0.6713 |
Remote Similarity |
NPD1608 |
Approved |
0.6707 |
Remote Similarity |
NPD1220 |
Phase 1 |
0.6707 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6693 |
Remote Similarity |
NPD2934 |
Approved |
0.6693 |
Remote Similarity |
NPD2933 |
Approved |
0.6691 |
Remote Similarity |
NPD228 |
Approved |
0.6686 |
Remote Similarity |
NPD6020 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6667 |
Remote Similarity |
NPD1653 |
Approved |
0.6647 |
Remote Similarity |
NPD5242 |
Approved |
0.6645 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6645 |
Remote Similarity |
NPD1196 |
Approved |
0.6645 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6644 |
Remote Similarity |
NPD259 |
Phase 1 |
0.6643 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6642 |
Remote Similarity |
NPD9379 |
Approved |
0.6642 |
Remote Similarity |
NPD9377 |
Approved |
0.6641 |
Remote Similarity |
NPD2860 |
Approved |
0.6641 |
Remote Similarity |
NPD2859 |
Approved |
0.6628 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6627 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6626 |
Remote Similarity |
NPD2296 |
Approved |
0.6624 |
Remote Similarity |
NPD1543 |
Discontinued |
0.6622 |
Remote Similarity |
NPD9537 |
Phase 1 |
0.6622 |
Remote Similarity |
NPD9536 |
Phase 1 |
0.6615 |
Remote Similarity |
NPD3020 |
Approved |
0.6613 |
Remote Similarity |
NPD9094 |
Approved |
0.661 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6609 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6605 |
Remote Similarity |
NPD37 |
Approved |
0.66 |
Remote Similarity |
NPD825 |
Approved |
0.66 |
Remote Similarity |
NPD826 |
Approved |
0.6599 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6588 |
Remote Similarity |
NPD1221 |
Approved |
0.6587 |
Remote Similarity |
NPD5710 |
Approved |
0.6587 |
Remote Similarity |
NPD5711 |
Approved |
0.6587 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6581 |
Remote Similarity |
NPD1195 |
Approved |
0.6577
|
Remote Similarity |
NPD3268 |
Approved |